Synthesis and cytotoxic activity of thiazolyl indolequinones

Anti-Cancer Drugs

Volumn 10, Issue 6, 1999, Pages 577-589

  Moody, Christopher J ^a   Roffey, Jonathan R A ^b   Swann, Elizabeth ^a,b   Lockyer, Stacey ^c   Houlbrook, Susan ^d   Stratford, Ian J ^c  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b LOUGHBOROUGH UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Bioreductive; Cytotoxicity; Indole; Quinone; Thiazole

Indexed keywords

QUINONE DERIVATIVE; UNINDEXED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SYNTHESIS; HAMSTER; HUMAN; HUMAN CELL; LUNG CARCINOMA; LUNG FIBROBLAST; NONHUMAN; PRIORITY JOURNAL;

EID: 0032872036     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199907000-00010     Document Type: Article

References (22)

1. 1. Nicolaou KC, Roschangar F, Vourloumis D. Chemical biology of epothilones. Angew Chem Int Ed Engl 1998; 37: 2015-45.
2. 2. Kane SA, Sasaki H, Hecht SM. Guanosine-specific DNA damage by a Co(II)bithiazole complex. J Am Chem Soc 1995; 117: 9107-18.
3. 3. Pettit GR, Kamano Y, Herald CL, et al. Antineoplastic agents. 136. The isolation and structure of a remarkable marine animal antineoplastic constituent - dolastatin 10. J Am Chem. Soc 1987; 109: 6883-5.
4. 4. Moody CJ, Bagley MC. Total synthesis of (+)-nostocyclamide. J Chem Soc Perkin Trans 1 1998; 601-7.
5. 5. Moody CJ, Bagley MC. The first synthesis of promothiocin A. Chem Commun 1998; 2049-50.
6. 6. Cotterill AS, Moody CJ, Mortimer RJ, et al. Cyclopropamitosenes, novel bioreductive anticancer agents. Synthesis, electrochemistry and biological activity of 7-substituted cyclopropamitosenes and related indolequinones. J Med Chem 1994; 37: 3834-43.
7. 7. Beall HD, Winski S, Swann E, et al. Indolequinone antitumor agents: correlation between quinone structure, rate of metabolism by recombinant human NQO1 and in vitro cytotoxicity. J Med Chem 1998; 41: 4755-66.
8. 8. Moody CJ, Swann E. Synthesis of the naturally occurring indolequinone BE 10988, an inhibitor of topoisomerase II. J Chem Soc Perkin Trans 1 1993; 2561-5.
9. 9. Oka H, Yoshinari T, Murai T, et al. A new topoisomerase-II inhibitor, BF-10988, produced by a Streptomycete. I. Taxonomy, fermentation, isolation and characterization. J Antibiot 1991; 44: 486-91.
10. 10. Suda H, Matsunaga K, Yamamura S, et al. Structure of a new topoisomerase II inhibitor BE 10988. Tetrahedron Lett 1991; 32: 2791-2.
11. 11. Suda H, Ohkubo M, Matsunaga K, et al. Total synthesis of a new topoisomerase inhibitor BE 10988. Tetrahedron Lett 1993; 34: 3797-8.
12. 12. Moody CJ, Swann E, Houlbrook S, et al. Synthesis and biological activity of thiazolyl indolequinones, analogues of the natural product BE 10988. J Med Chem 1995; 38: 1039-43.
13. 13. Moody CJ, Roffey JRA, Stephens MA, et al. Synthesis and cytotoxic activity of indolyl thiazoles. Anti-Cancer Drugs 1997; 8: 489-99.
14. 14. Carmichael J, Degraff WG, Gazdar AF, et al. Evaluation of a tetrazolium-based semi-automated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987; 47: 936-42.
15. 15. Stratford IJ, Stephens MA. The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay. Int J Radiat Oncol Biol Phys 1989; 16: 973-6.
16. 16. Kirk J, Houlbrook S, Stuart NSA, et al. Differential modulation of doxorubicin toxicity to multidrug and intrinsically drug resistant cell lines by anti-oestrogens and their major metabolites. Br J Cancer 1993; 67: 1189-95.
17. 17. Smith K, Houlbrook S, Greenall M, et al. Topoisomerase IIα co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to mAMSA and mitoxantrone sensitivity. Oncogene 1993; 8: 933-8.
18. 18. Houlbrook S, Carmichael J, Davies S, et al. Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines. Br J Cancer 1995; 72: 1454-61.
19. 19. Houlbrook S, Harris AL, Carmichael J, et al. Relationship between topoisomerase II levels and resistance to topoisomerase II inhibitors in lung cancer cell ines. Anticancer Res 1996; 16: 1603-10.
20. 20. Houlbrook S, Kirk J, Stuart NSA, et al. Human tumor cell lines: a valuable method for the evaluation of new drugs and for the evaluation of mechanisms underlying cytotoxic drug resistance. Oncol Life Sci Adv 1994; 13: 69-76.
21. 21. Lafleur MVM, Wijker CA, Westmijze EJ, et al. DNA Damage due to aziridine containing bioreductive drugs. Ninth Int Conf on Chemical Modifiers of Cancer Treatment 1995; 1-22.
22. 22. Moody CJ, O'Sullivan N, Stratford IJ, et al. Cyclopropamitosenes: novel bioreductive anticancer agents-mechanism of action and enzymic reduction. Anti-Cancer Drugs 1994; 5: 367-72.